Logotype for Haoxi Health Technology Limited

Haoxi Health Technology (HAO) Q4 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Haoxi Health Technology Limited

Q4 2026 earnings summary

30 Sep, 2026

Executive summary

  • The company operates as a holding entity with its main business conducted through a wholly owned PRC subsidiary, focusing on online marketing solutions for healthcare advertisers in China.

  • Revenue is generated from providing one-stop online marketing services, especially short video ads, with a client base primarily in the healthcare sector.

  • The company experienced significant revenue volatility over the past three years, with a sharp increase in FY2026 but a swing from net income to a substantial net loss.

  • The business is highly dependent on a single supplier, Ocean Engine (ByteDance), and faces intense competition and regulatory risks in China.

  • The company completed several equity financings and share structure changes, including multiple reverse splits and an increase in Class B share voting rights.

Financial highlights

  • FY2026 revenue was $54.83 million, up 67% from $32.80 million in FY2025, which had declined 32% from $48.52 million in FY2024.

  • Net loss for FY2026 was $9.54 million, compared to net income of $3.88 million in FY2025 and $1.29 million in FY2024.

  • Gross margin declined to 1.15% in FY2026 from 2.83% in FY2025 and 5.67% in FY2024, due to higher costs and lower rebates from media partners.

  • General and administrative expenses rose sharply to $8.61 million in FY2026, mainly due to a $6.02 million allowance for credit losses and increased labor costs.

  • Cash and cash equivalents at June 30, 2026 were $10.93 million, with net cash used in operating activities of $2.57 million and net cash provided by financing activities of $9.32 million.

  • The company recognized a $1.5 million impairment loss on intangible assets in FY2026 and a $6.07 million allowance for credit losses.

Outlook and guidance

  • Management expects continued investment in R&D and technology, particularly in its Bidding Compass software, and plans to expand its advertiser base in the healthcare sector.

  • The company does not anticipate paying dividends in the foreseeable future, prioritizing business expansion and liquidity.

  • Capital expenditures are expected to increase moderately over the next two to three years to support business growth.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Haoxi Health Technology